Institution Directory

Clinical trials at Fred Hutchinson Cancer Center

Sites in Seattle, WA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

594

Shown on this page

Current sort

Live official records

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions: CHS-114, toripalimab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma-1b, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: PF-06821497, Docetaxel, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 70
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more

Conditions: Solid Tumours
Interventions: BMS-986517, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Irvine, California • Los Angeles, California • Orange, California + 6 more

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere); Drug · Combination Product
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Sacramento, California • Celebration, Florida • Miami, Florida + 10 more

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Enzalutamide, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neoplasms
Interventions: Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 10 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 24
States / cities: Duarte, California • Stanford, California • Denver, Colorado + 19 more

Conditions: GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour, Gastrointestinal Tumors
Interventions: KQB198, Imatinib (Gleevec); Drug
Lead sponsor: Kumquat Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 14 more

Conditions: Barrett's Esophagus, Esophageal Neoplasm
Interventions: Balloon Capsule Device, Endoscopy; Device · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2028
U.S. locations: 10
States / cities: Baltimore, Maryland • Rochester, Minnesota • St Louis, Missouri + 5 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 8
States / cities: Palo Alto, California • Sarasota, Florida • Boston, Massachusetts + 4 more

Conditions: Ovarian Carcinoma
Interventions: Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging; Procedure · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 1,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2047
U.S. locations: 564
States / cities: Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more

About this Fred Hutchinson Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Fred Hutchinson Cancer Center in Seattle, WA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Fred Hutchinson Cancer Center

Filter and sort this campus

Live official records

Study of CHS-114 in Participants With Advanced Solid Tumors

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

About this Fred Hutchinson Cancer Center institution page